Kachnic LA (2007) Adjuvant chemoradiation for localized rectal cancer: current trends and future directions. Gastrointest Cancer Res. 1:S64–72.

Schrag D, Shi Q, Weiser MR et al (2023) Preoperative treatment of locally advanced rectal cancer. N Engl J Med 389(4):322–334. https://doi.org/10.1056/NEJMoa2303269

Article  CAS  PubMed  PubMed Central  Google Scholar 

O’Brien T, Hospers G, Conroy T et al (2024) The role of total neoadjuvant therapy in locally advanced rectal cancer: a survey of specialists attending the All-Ireland Colorectal Cancer Conference 2022, including lead investigators of OPRA, PRODIGE-23, and RAPIDO. Ir J Med Sci 193(3):1183–1190. https://doi.org/10.1007/s11845-023-03591-4

Article  PubMed  Google Scholar 

Glynne-Jones R, Wyrwicz L, Tiret E, et al (2018) Rectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment, and follow-up [published correction appears in Ann Oncol. 29:iv263. https://doi.org/10.1093/annonc/mdy161].

Abraha I, Aristei C, Palumbo I, et al (2018) Preoperative radiotherapy and curative surgery for the management of localised rectal carcinoma. Cochrane Database Syst Rev 10(10):CD002102. https://doi.org/10.1002/14651858.CD002102.pub3

Johnson GGRJ, Park J, Helewa RM, Goldenberg BA, Nashed M, Hyun E (2023) Total neoadjuvant therapy for rectal cancer: a guide for surgeons. Can J Surg 66(2):E196-E201. https://doi.org/10.1503/cjs.005822

Liu S, Jiang T, Xiao L et al (2021) Total neoadjuvant therapy (TNT) versus standard neoadjuvant chemoradiotherapy for locally advanced rectal cancer: a systematic review and meta-analysis. Oncologist 26(9):e1555–e1566. https://doi.org/10.1002/onco.13824

Article  CAS  PubMed  PubMed Central  Google Scholar 

Petrelli F, Trevisan F, Cabiddu M et al (2020) Total neoadjuvant therapy in rectal cancer: a systematic review and meta-analysis of treatment outcomes. Ann Surg 271(3):440–448. https://doi.org/10.1097/SLA.0000000000003471

Article  PubMed  Google Scholar 

Ghalehtaki R, Nourbakhsh F, Abyaneh R et al (2024) Optimal sequence for total neoadjuvant therapy in locally advanced rectal cancer: an evidence-based review. Cancer Med 13(19):e70291. https://doi.org/10.1002/cam4.70291

Article  PubMed  PubMed Central  Google Scholar 

Kasi A, Abbasi S, Handa S et al (2020) Total neoadjuvant therapy vs standard therapy in locally advanced rectal cancer: a systematic review and meta-analysis. JAMA Netw Open 3(12):e2030097. https://doi.org/10.1001/jamanetworkopen.2020.30097

Article  PubMed  PubMed Central  Google Scholar 

Şenocak Taşçı E, Mutlu AU, Saylık O, et al (2024) Total neoadjuvant therapy versus neoadjuvant chemoradiation for locally advanced rectal cancer: a multi-institutional real-world study. Cancers (Basel) 16(18):3213.

Denost Q, Frison E, Salut C et al (2021) A phase III randomized trial evaluating chemotherapy followed by pelvic reirradiation versus chemotherapy alone as preoperative treatment for locally recurrent rectal cancer - GRECCAR 15 trial protocol. Colorectal Dis 23(7):1909–1918. https://doi.org/10.1111/codi.15670

Article  CAS  PubMed  Google Scholar 

PelvEx Collaborative. Induction chemotherapy followed by chemoradiotherapy versus chemoradiotherapy alone as neoadjuvant treatment for locally recurrent rectal cancer: study protocol of a multicentre, open-label, parallel-arms, randomized controlled study (PelvEx II). BJS Open. 2021;5(3):zrab029. https://doi.org/10.1093/bjsopen/zrab029.

Rödel C, Arnold D, Becker H et al (2010) Induction chemotherapy before chemoradiotherapy and surgery for locally advanced rectal cancer : is it time for a randomized phase III trial? Strahlenther Onkol 186(12):658–664. https://doi.org/10.1007/s00066-010-2194-2

Article  PubMed  Google Scholar 

Conroy T, Castan F, Etienne PL et al (2024) Total neoadjuvant therapy with mFOLFIRINOX versus preoperative chemoradiotherapy in patients with locally advanced rectal cancer: long-term results of the UNICANCER-PRODIGE 23 trial. Ann Oncol 35(10):873–881. https://doi.org/10.1016/j.annonc.2024.06.019

Article  CAS  PubMed  Google Scholar 

Bandidwattanawong C (2024) Total neoadjuvant therapy for locally advanced rectal cancer: how to select the most suitable? J Clin Med. 13(17):5061. https://doi.org/10.3390/jcm13175061

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ouyang GL, Meng WJ, Shu P et al (2019) Zhonghua Wei Chang Wai Ke Za Zhi 22(4):349–356. https://doi.org/10.3760/cma.j.issn.1671-0274.2019.04.007

Article  CAS  PubMed  Google Scholar 

Zhai ZW, Zhang KN, Wang C et al (2020) Zhonghua Wei Chang Wai Ke Za Zhi 23(3):274–280. https://doi.org/10.3760/cma.j.cn.441530-20190819-00312

Article  CAS  PubMed  Google Scholar 

Zhang X, Ma S, Guo Y, Luo Y, Li L (2022) Total neoadjuvant therapy versus standard therapy in locally advanced rectal cancer: a systematic review and meta-analysis of 15 trials. PLoS One. 17(11). https://doi.org/10.1371/journal.pone.0276599

Zhang Y, Tang Y, Ma H, et al (2024) Number of lymph nodes retrieved in patients with locally advanced rectal cancer after total neoadjuvant therapy: post-hoc analysis from the STELLAR trial. BJS Open. 8(5):zrae118. https://doi.org/10.1093/bjsopen/zrae118

Kasi A, Abbasi S, Handa S et al (2020) Total neoadjuvant therapy vs standard therapy in locally advanced rectal cancer: a systematic review and meta-analysis. JAMA Netw Open. 3(12). https://doi.org/10.1001/jamanetworkopen.2020.30097

Mihmanlı M, Kabul Gürbulak E, Akgün İE et al (2016) Delaying surgery after neoadjuvant chemoradiotherapy improves prognosis of rectal cancer. World J Gastrointest Oncol 8(9):695–706. https://doi.org/10.4251/wjgo.v8.i9.695

Article  PubMed  PubMed Central  Google Scholar 

Koukourakis IM, Kouloulias V, Tiniakos D, Georgakopoulos I, Zygogianni A (2023) Current status of locally advanced rectal cancer therapy and future prospects. Crit Rev Oncol Hematol 186:103992. https://doi.org/10.1016/j.critrevonc.2023.103992

Article  PubMed  Google Scholar 

Glynne-Jones R, Counsell N, Quirke P et al (2014) Chronicle: results of a randomised phase III trial in locally advanced rectal cancer after neoadjuvant chemoradiation randomising postoperative adjuvant capecitabine plus oxaliplatin (XELOX) versus control. Ann Oncol 25(7):1356–1362. https://doi.org/10.1093/annonc/mdu147

Article  CAS  PubMed  Google Scholar 

Bahadoer RR, Dijkstra EA, van Etten B, et al (2021) Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3 trial [published correction appears in Lancet Oncol. 2021 22(2):e42. https://doi.org/10.1016/S1470-2045(20)30781-6].

Rödel C, Graeven U, Fietkau R et al (2015) Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial. Lancet Oncol 16(8):979–989. https://doi.org/10.1016/S1470-2045(15)00159-X

Article  CAS  PubMed  Google Scholar 

Zhao L, Liu R, Zhang Z et al (2016) Oxaliplatin/fluorouracil-based adjuvant chemotherapy for locally advanced rectal cancer after neoadjuvant chemoradiotherapy and surgery: a systematic review and meta-analysis of randomized controlled trials. Colorectal Dis 18(8):763–772. https://doi.org/10.1111/codi.13381

Article  CAS  PubMed  Google Scholar 

Gerard JP, Glynne-Jones R, Blackstock W, Aschele C, van de Velde C (2003) Radiochemotherapy in rectal cancer: the role of oxaliplatin. Colorectal Dis 5(Suppl 3):29–35. https://doi.org/10.1046/j.1463-1318.5.s3.4.x

Article  PubMed  Google Scholar 

Bosset JF, Calais G, Mineur L et al (2014) Fluorouracil-based adjuvant chemotherapy after preoperative chemoradiotherapy in rectal cancer: long-term results of the EORTC 22921 randomised study. Lancet Oncol 15(2):184–190. https://doi.org/10.1016/S1470-2045(13)70599-0

Article  CAS  PubMed  Google Scholar 

Cats A, Jansen EPM, van Grieken NCT et al (2018) Chemotherapy versus chemoradiotherapy after surgery and preoperative chemotherapy for resectable gastric cancer (CRITICS): an international, open-label, randomised phase 3 trial. Lancet Oncol 19(5):616–628. https://doi.org/10.1016/S1470-2045(18)30132-3

Article  CAS  PubMed  Google Scholar 

Hofheinz RD, Wenz F, Post S et al (2012) Chemoradiotherapy with capecitabine versus fluorouracil for locally advanced rectal cancer: a randomised, multicentre, non-inferiority, phase 3 trial. Lancet Oncol 13(6):579–588. https://doi.org/10.1016/S1470-2045(12)70116-X

Article  CAS  PubMed  Google Scholar 

Hofheinz RD, Wenz F, Post S et al (2012) Chemoradiotherapy with capecitabine versus fluorouracil for locally advanced rectal cancer: a randomised, multicentre, non-inferiority, phase 3 trial. Lancet Oncol 13(6):579–588. https://doi.org/10.1016/S1470-2045(12)70116-X

Article  CAS  PubMed  Google Scholar 

Hong YS, Nam BH, Kim KP et al (2014) Oxaliplatin, fluorouracil, and leucovorin versus fluorouracil and leucovorin as adjuvant chemotherapy for locally advanced rectal cancer after preoperative chemoradiotherapy (ADORE): an open-label, multicentre, phase 2, randomised controlled trial. Lancet Oncol 15(11):1245–1253. https://doi.org/10.1016/S1470-2045(14)70377-8

Article  CAS  PubMed  Google Scholar 

Fokas E, Allgäuer M, Polat B et al (2019) Randomized phase II trial of chemoradiotherapy plus induction or consolidation chemotherapy as total neoadjuvant therapy for locally advanced rectal cancer: CAO/ARO/AIO-12. J Clin Oncol 37(34):3212–3222. https://doi.org/10.1200/JCO.19.00308

Article  CAS  PubMed  Google Scholar 

Cui J, Fang H, Zhang L, Wu YL, Zhang HZ (2016) Advances for achieving a pathological complete response for rectal cancer after neoadjuvant therapy. Chronic Dis Transl Med. 2(1):10–16. https://doi.org/10.1016/j.cdtm.2016.06.001